Mid-Market Account Manager
FleetioFull Time
Mid-level (3 to 4 years), Senior (5 to 8 years)
Candidates should possess a Bachelor's degree in life science, biology, business, or marketing, with an MBA preferred. A minimum of 3 years of direct account management experience in molecular diagnostics, preferably with MRD testing, is required, along with a proven track record of revenue generation in the diagnostic, pharmaceutical, or biotechnology sectors. Experience working with major cancer centers, oncology GPOs, large health systems, and oncology practices is essential. The role demands comfort in engaging with executive-level stakeholders, an in-depth understanding of the payer and reimbursement environment in oncology diagnostics, and proficiency in Microsoft Office products and Salesforce.com. Strong independent work ethic, communication, project management, prioritization, cross-functional relationship building, and advanced presentation and business acumen skills are necessary.
The MRD Clinical Account Executive will drive the adoption of Tempus's MRD testing services within their territory, engaging with KOLs, clinicians, and decision-makers to establish and expand business. Responsibilities include developing strategic plans for client acquisition and retention, maximizing client-bill contracting opportunities, and implementing laboratory services agreements. The role involves collaborating with internal sales roles to achieve company goals, identifying partnership opportunities, and providing market feedback to leadership. A comprehensive business plan for the territory, including budgets and goal setting, must be developed and implemented, while consistently representing Tempus's company culture with integrity.
AI-driven healthcare data analysis platform
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.